Lower Limb Spasticity
Conditions
Brief summary
The objective of this study is to demonstrate the effect of intramuscular BoNT-A injections in relieving pain, in a broad population of patients who suffer pain as the primary problem associated with spasticity. Thus, this study will help to expand the information that is available regarding the impact of BoNT-A treatment in routine clinical practice conditions. Treatment goals can vary greatly from one patient to another and there is no unique, single outcome that reflects the treatment benefits in all the cases. Therefore, this study with special focus on the achievement of therapeutic goals, will allow the identification of each patient's specific goals regarding the improvement of the functional outcomes, the quality of life and patient well-being.
Interventions
BIOLOGICALBotulinum toxin type A
This is an observational study designed to reflect the clinical practice in real life as closely as possible. Botulinum Toxin Type A (BoNT-A) injection administered according to the local Summary of Product Characteristics (SmPC) and the locally agreed treatment guidelines.
Sponsors
Ipsen
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men or women age 18 years and above * Post-stroke lower-limb spasticity * Prior agreement with the patient to inject BoNT-A * If previously treated with BoNT-A, (at least 3 months interval between last injection and inclusion). * Therapeutic goals agreed jointly with the patient * Functional Ambulation Classification (FAC) score 2-5 * Capacity to comply with the protocol * Written informed consent
Exclusion criteria
* Documented positive antigenicity to botulinum toxin * Neuromuscular disease * Use of medications that interfere with neuromuscular transmission * Severe muscle atrophy in any muscle to be injected * Any other indication that might interfere with rehabilitation or the evaluation of results * Any non-stroke spasticity diagnosis * Pregnancy or nursing mothers * Previous participation in any study using Goal Attainment Scale (GAS)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Pain relief on Numeric Rating Scale | Baseline visit and every 4 months up to 16 months (Visit 5). | Pain relief evaluated by Numeric Rating Scale (NRS). The NRS score for patient self-reporting of pain ranging from 0 (no pain) to 10 (the most severe pain). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Pain relief on Visual Assessment Scale | Baseline visit and every 4 months up to 16 months (Visit 5). | Pain relief evaluated by measuring changes in Visual Assessment Scale (VAS). The VAS used a 100 mm line in which values were reported, 0 (no pain) to 10 (the most severe pain). |
| Responder rate using goal Attainment Scale | Every 4 months up to 16 months (Visit 5). | Responder rate assessed on the Goal Attainment Scale (GAS). GAS is a 5-point scale, with the degree of attainment captured for each goal area. |
Countries
Spain
Outcome results
None listed